The pharmaceutical consulting industry in the US plays a crucial role in guiding biotech and pharmaceutical companies through the complex phases of drug development and market entry. This sector includes consultancy firms specializing in regulatory compliance, clinical trial management, and market access strategies. Companies within this space also offer advisory services related to pricing and reimbursement implications, helping firms navigate ever-changing healthcare policies. As the industry evolves, trends like digital health solutions and AI-driven drug discovery are gaining ground, underscoring the increasing promise of technology in healthcare innovation and improving patient outcomes. This growth journey invites fresh thinking and investment.


The list of top pharmaceutical consulting investors features a mix of venture capital firms and corporate giants, primarily located in metropolitan hubs like New York and California. Founded from 1849 to 2016, these 13 investors vary from small teams of less than 50 to large organizations employing over 10,000 staff. In the past year, they've made an impressive combined total of 797 investments, emphasizing their active role in supporting new ventures in the pharmaceutical consulting space. Investors like GV and Pfizer demonstrate a commitment to innovation and growth in healthcare, shaping the industry's future.


Top 13 Pharmaceutical Consulting Investors in the US


1. OrbiMed

  • Website: orbimed.com
  • Type: Venture Capital
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 1989
  • Headcount: 51-200
  • Number of deals in 2024: 52
  • LinkedIn: orbimed-advisors

OrbiMed is a prominent investment firm based in New York, specializing in healthcare investments since its founding in 1989. With approximately $17 billion in assets under management, OrbiMed focuses on biopharmaceuticals, medical devices, and healthcare services. The firm has been actively involved in various significant transactions within the pharmaceutical consulting context. For instance, they led the Series A financing for Harvest Integrated Research Organization, a clinical research organization, which aims to enhance its capabilities in digital clinical research management and multilateral clinical trials. Additionally, OrbiMed participated in the Series C financing for Crown Bioscience, which is dedicated to integrated cancer drug discovery and translational oncology. Their investments in Insilico Medicine, a company focused on AI-driven drug discovery, further highlight their commitment to advancing innovation in the pharmaceutical sector. OrbiMed's diverse portfolio and strategic investments position them as a key player in the healthcare investment landscape.


2. Y Combinator

  • Website: ycombinator.com
  • Type: Venture Capital
  • Headquarters: San Francisco, California, United States (USA)
  • Founded year: 2005
  • Headcount: 51-200
  • Number of deals in 2024: 802
  • LinkedIn: y-combinator

Y Combinator is a prominent startup accelerator and venture capital firm based in San Francisco, California, founded in 2005. It provides funding and mentorship to early-stage technology companies through a structured program that helps entrepreneurs launch and grow their businesses. Y Combinator has successfully launched over 4,000 startups, making it a key player in the technology startup ecosystem. Among its notable investments, Y Combinator has backed H1.co, a healthcare data platform that raised significant funding in multiple rounds, and Atomwise, a company specializing in AI for drug discovery, which raised $163 million CAD in a Series B round and $45 million in a Series A round. These investments highlight Y Combinator's engagement with companies that have a direct impact on the pharmaceutical consulting industry.


3. Perceptive Advisors


Perceptive Advisors is an investment firm based in New York, specializing in the life sciences sector. Founded in 1999, the firm provides capital solutions and investment management services to both private and public healthcare companies, with a strong focus on biotechnology, pharmaceuticals, and medical devices. Their expertise aids clients in securing funding for innovation and growth within the healthcare industry. Notable transactions include participation in Prometheus Bio's $130 million equity financing aimed at developing therapies for inflammatory bowel diseases, and involvement in Cidara Therapeutics' $42 million Series B funding, which supports the development of novel therapeutics. Additionally, they contributed to ReViral's Series C financing to advance clinical development for antiviral therapies, and supported CinCor Pharma's $143 million Series B financing for hypertension treatments. These transactions highlight Perceptive Advisors' active role in the pharmaceutical consulting landscape, reinforcing their commitment to advancing healthcare solutions.


4. New Enterprise Associates (NEA)

  • Website: nea.com
  • Type: Venture Capital
  • Headquarters: Menlo Park, California, United States (USA)
  • Founded year: 1977
  • Headcount: 51-200
  • Number of deals in 2024: 57
  • LinkedIn: new-enterprise-associates

New Enterprise Associates (NEA) is a prominent venture capital firm founded in 1977, based in Menlo Park, California. With a focus on investment management and advisory services, NEA specializes in supporting startups, particularly in the technology and healthcare sectors. The firm emphasizes long-term relationships with entrepreneurs, providing not only funding but also strategic guidance to help navigate the complexities of building successful businesses. NEA has been involved in significant transactions within the pharmaceutical consulting context, such as leading funding rounds for Aetion, a healthcare technology company that raised substantial capital to enhance its evidence platform and expand its market presence. Additionally, NEA participated in funding Predictive Biosciences, which is focused on developing diagnostic assays for bladder cancer, showcasing their commitment to advancing healthcare solutions. These transactions highlight NEA's active role in the pharmaceutical consulting landscape, making them a relevant investor in this field.


5. ARCH Venture Partners

  • Website: archventure.com
  • Type: Venture Capital
  • Headquarters: Chicago, Illinois, United States (USA)
  • Founded year: 1986
  • Headcount: 11-50
  • Number of deals in 2024: 32
  • LinkedIn: arch-venture-partners

ARCH Venture Partners is a venture capital firm based in Chicago, Illinois, founded in 1986. The firm specializes in biotechnology investments, providing funding and strategic support to innovative companies in the life sciences sector. Their primary clientele consists of early-stage biotech firms that are focused on developing groundbreaking medical solutions. In 2024, ARCH Venture Partners has been particularly active, participating in notable transactions such as the $1 billion Series A funding for Xaira Therapeutics, which is leveraging AI for drug discovery and development. They also invested in Advanced Medicine Partners, which raised $32 million, and Vilya, which secured $21 million in funding. These investments highlight their commitment to supporting companies that are at the forefront of pharmaceutical innovation and consulting.


6. Sosv

  • Website: sosv.com
  • Type: Venture Capital
  • Headquarters: United States (USA)
  • Founded year: 1995
  • Headcount: 51-200
  • Number of deals in 2024: 170
  • LinkedIn: sosv

SOSV is a venture capital firm founded in 1995, specializing in funding and supporting deep tech startups through its development programs. With a global reach, SOSV connects innovative companies with investors, providing not just capital but also resources to help startups grow and succeed. In the pharmaceutical consulting context, SOSV has been involved in significant transactions such as Ten63 Therapeutics, which raised multiple rounds of funding, including a Series A round aimed at exploring small molecule drug structures using generative AI. This focus on health technology, alongside their investment in other sectors like climate technology, showcases their commitment to advancing innovations that can impact the pharmaceutical industry.


7. Pfizer

  • Website: pfizer.com
  • Type: Corporate
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 1849
  • Headcount: 10001+
  • Number of deals in 2024: 10
  • LinkedIn: pfizer

Pfizer Inc. is a leading pharmaceutical and biotechnology company based in New York, founded in 1849. With over 10,000 employees, Pfizer develops and produces a wide range of medicines and vaccines aimed at improving patient health outcomes globally. In 2022, Pfizer acquired GBT, a company specializing in treatments for sickle cell disease, showcasing its commitment to addressing urgent health needs. Additionally, Pfizer has been involved in significant funding rounds for Nimbus Therapeutics, a biotechnology firm focused on immunology, oncology, and metabolic diseases. Notably, Pfizer participated in a $65 million funding round for Nimbus, which aims to accelerate the development of new therapies. These transactions highlight Pfizer's strategic investments in innovative healthcare solutions, reinforcing its role as a key investor in the pharmaceutical consulting landscape.


8. Casdin Capital, LLC

  • Website: casdincapital.com
  • Type: Venture Capital
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 2012
  • Headcount: 11-50
  • Number of deals in 2024: 9
  • LinkedIn: casdin-capital-llc

Casdin Capital, LLC is a New York-based venture capital firm founded in 2012, specializing in the life sciences sector. The firm focuses on investing in healthcare, biotechnology, synthetic biology, and technology, providing funding and strategic partnerships to innovative companies. Casdin Capital's investment strategy is evident in their participation in notable transactions such as TrialSpark, a next-generation pharma company that raised $156 million in Series C funding, and Recursion Pharmaceuticals, which secured $239 million in Series D funding. Additionally, they were involved in Treeline Biosciences' $212 million Series A funding and Insitro's $400 million Series C round. These investments highlight Casdin Capital's commitment to advancing research and development in the pharmaceutical industry, making them a valuable player in the life sciences ecosystem.


9. Invus

  • Website: invus.com
  • Type: Venture Capital
  • Headquarters: New York, New York, United States (USA)
  • Founded year: 1985
  • Headcount: 51-200
  • Number of deals in 2024: 35
  • LinkedIn: invus

Invus is a New York-based investment firm specializing in equity investments and investment management, founded in 1985. The firm partners with owner-managers across various industries to enhance business performance and create sustainable value. With a global focus, Invus leverages its expertise to navigate complex investment landscapes. In recent years, Invus has made significant investments in the pharmaceutical sector, including a participation in Recursion Pharmaceuticals' private placement, which raised approximately $150 million, and a $41.5 million private placement for Aravive Biologics aimed at funding pivotal clinical trials. Additionally, they were involved in a $190 million Series B funding for Valo Health, a company focused on transforming drug discovery and development. These transactions highlight Invus's commitment to supporting innovative companies in the pharmaceutical and biotechnology fields.


10. GV (Google Ventures)

  • Website: gv.com
  • Type: Venture Capital
  • Headquarters: San Francisco Bay Area, California, United States (USA)
  • Founded year: 2009
  • Headcount: 51-200
  • Number of deals in 2024: 74
  • LinkedIn: gv

GV (Google Ventures) is a venture capital firm founded in 2009, based in the San Francisco Bay Area, California. With over $10 billion in assets under management, GV focuses on various sectors, including life sciences and artificial intelligence. The firm partners with innovative technology startups, providing funding and support to help them navigate the challenges of building successful companies. Notably, GV has invested in several pharmaceutical-related companies, such as Nimbus Therapeutics, which raised $210 million in a private equity round, and Treeline Biosciences, which secured $212 million in a Series A funding round. Additionally, GV participated in the Series B financing of Forty Seven, a company developing an antibody for cancer treatment, highlighting their commitment to advancing healthcare solutions. These transactions underscore GV's active role in the pharmaceutical sector, making them a relevant player in the pharmaceutical consulting landscape.


11. Janus Henderson Investors

  • Website: janushenderson.com
  • Type: Private Equity
  • Headquarters: Denver, Colorado, United States (USA)
  • Founded year: 2017
  • Headcount: 1001-5000
  • Number of deals in 2024: 39
  • LinkedIn: janus-henderson-emea

Janus Henderson Investors is a private equity firm based in Denver, Colorado, founded in 2017. The firm specializes in asset management, offering a diverse range of investment products including ETFs, mutual funds, and managed accounts. With a global presence and a focus on disciplined investment strategies, Janus Henderson serves individual investors, financial professionals, and institutional clients. Notably, the firm has participated in significant financing rounds within the pharmaceutical sector, including a Series D investment in Decibel Therapeutics, which raised $82.2 million to support its therapeutic pipeline, and a Series D round for FORMA Therapeutics, which secured $100 million for clinical development in sickle cell disease. These transactions highlight Janus Henderson's active role in the pharmaceutical consulting landscape, making them a relevant player in this field.


12. Frazier Healthcare Partners


Frazier Healthcare Partners is a Seattle-based venture capital firm founded in 1991, specializing in healthcare and life sciences investments. The firm focuses on growth buyout investments in profitable healthcare businesses and innovative biopharmaceuticals. With a portfolio that includes notable transactions such as the acquisition of Apollo Intelligence, a provider of real-time data and insights for the healthcare and life sciences industries, Frazier Healthcare Partners aims to accelerate growth and innovation in these sectors. They also acquired Packaging Coordinators, Inc. from Catalent Pharma Solutions, which enhances their involvement in pharmaceutical packaging operations. Furthermore, their investment in Sierra Oncology and Marcadia Biotech highlights their commitment to advancing drug development and biopharmaceutical innovations. Overall, Frazier Healthcare Partners is dedicated to supporting healthcare companies seeking capital to scale operations and enhance service offerings, making them a significant player in the pharmaceutical consulting landscape.


13. Vivo Capital

  • Website: vivocapital.com
  • Type: Venture Capital
  • Headquarters: Palo Alto, California, United States (USA)
  • Founded year: 1996
  • Headcount: 51-200
  • Number of deals in 2024: 19
  • LinkedIn: vivo-capital

Vivo Capital is a venture capital firm founded in 1996, based in Palo Alto, California, specializing in healthcare investments. The firm provides venture capital, private equity, and public equity investments to healthcare companies, facilitating innovation and growth in the sector. Vivo Capital has been involved in several notable transactions, including the acquisition of Serán Bioscience, a contract development and manufacturing organization, which highlights their strategic interest in pharmaceutical consulting and development. They also participated in significant funding rounds for companies like Sierra Oncology, which raised $59.5 million in Series D funding, and TOT BIOPHARM, which completed a $102 million Series B financing round. These transactions reflect Vivo Capital's commitment to advancing healthcare technologies and products, making them a key player in the pharmaceutical consulting industry.



Pharmaceutical Consulting Insights: Key Investors in the US


InvestorHeadquarterSizeFoundedDeals 2024
OrbiMedNew York, New York, United States (USA)51-200198952
Y CombinatorSan Francisco, California, United States (USA)51-2002005802
Perceptive AdvisorsNew York, New York, United States (USA)11-50199945
New Enterprise Associates (NEA)Menlo Park, California, United States (USA)51-200197757
ARCH Venture PartnersChicago, Illinois, United States (USA)11-50198632
SosvUnited States (USA)51-2001995170
PfizerNew York, New York, United States (USA)10001+184910
Casdin Capital, LLCNew York, New York, United States (USA)11-5020129
InvusNew York, New York, United States (USA)51-200198535
GV (Google Ventures)San Francisco Bay Area, California, United States (USA)51-200200974
Janus Henderson InvestorsDenver, Colorado, United States (USA)1001-5000201739
Frazier Healthcare PartnersSeattle, Washington, United States (USA)51-200199127
Vivo CapitalPalo Alto, California, United States (USA)51-200199619


Want to find more investors focusing on the pharmaceutical consulting industry?

If you want to find more investors that are active in the pharmaceutical consultingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!